Allergies & Asthma

SAN FRANCISCO — For neighborhoods near a major coking operation in Pittsburgh, its shutdown at the end of 2015 was followed by markedly lower rates of respiratory disease hospitalizations, researchers reported here. Inpatient admissions for chronic obstructive pulmonary disease (COPD) among area residents were steadily increasing during 2013 to 2015. But from 2016 onward, they
0 Comments
As if sneezing and itching wasn’t enough, some people experience heartburn symptoms due to their environmental and/or food allergies. Eosinophilic esophagitis (EoE) might be to blame. It can be allergy-related, but mainly causes reactions that impact your digestive system. The first official EoE diagnosis was in the 1990s, but there’s been an increase in diagnoses and ongoing research
0 Comments
While the risk of anaphylaxis after administration of IV iron product was low among older adults, it was more common after certain iron products, researchers found. The highest adjusted incidence rates for anaphylaxis among Medicare recipients receiving IV iron was 9.8 cases (95% CI 6.2-15.3) per 10,000 first administrations of iron dextran (Dexferrum) and 4.0
0 Comments
The intranasal live attenuated flu vaccine is just as safe for children with asthma as the intramuscular inactivated vaccine, a small clinical trial suggested. Within 42 days of vaccination, 10.8% of children who received the intranasal quadrivalent live attenuated influenza vaccine (LAIV4) experienced an asthma exacerbation compared with 14.7% of those who received the intramuscular
0 Comments
Doctors, scientists, and patient advocates described the tremendous harms of burn pits to active duty service members and veterans, ranging from cancers to severe respiratory illness and death, during a hearing of the Senate Committee on Armed Services Subcommittee on Personnel on Wednesday. Subcommittee Chair Kirsten Gillibrand (D-N.Y.) opened the hearing by stating that service
0 Comments
Patients with hereditary angioedema who were treated with an antisense oligonucleotide treatment, donidalorsen, experienced significantly fewer attacks than patients who received placebo, a phase II trial showed. Over 17 weeks, the mean number of investigator-confirmed angioedema attacks was 0.23 per month among the 14 patients treated with donidalorsen 80 mg every 4 weeks compared with
0 Comments
PHOENIX — Exacerbation-prone asthma patients who had high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO) appeared to benefit from lebrikizumab, pooled data from two disappointing phase III trials suggested. In the post-hoc analysis of LAVOLTA I and LAVOLTA II, patients with at least one exacerbation in the prior year who had high
0 Comments
PHOENIX — Patients with severe, uncontrolled asthma experienced greater relief throughout the year when treated with the biologic tezepelumab (Tezspire) versus placebo, according to findings from the phase III NAVIGATOR study. Over 52 weeks, tezepelumab significantly reduced the annualized asthma exacerbation rate by 56% in the overall study population (P<0.001), and by 41% in those
0 Comments
PHOENIX — Adding mepolizumab (Nucala) to guideline-based care reduced flare-ups in disadvantaged kids with exacerbation-prone, eosinophilic asthma, the yearlong MUPPITS-2 trial showed. In the randomized study of nearly 300 kids living in urban parts of the U.S., the annualized exacerbation rate was 0.96 with mepolizumab versus 1.30 with placebo, representing a 27% relative decrease (rate
0 Comments
PHOENIX — Experts in lung diseases debated at the annual meeting of the American Academy of Allergy, Asthma & Immunology here whether at-home spirometry tests and devices, which are now available from multiple companies, should be elevated to prime-time use. The tests are good enough to allow patients to monitor their lung function at home
0 Comments
PHOENIX — In some patients with eosinophilic asthma, dupilumab (Dupixent) offered the highest chance of better lung function, although the agent also carried the highest odds of serious adverse events (AEs), a researcher reported. In an indirect treatment comparison of dupilumab, mepolizumab (Nucala), and benralizumab (Fasenra), patients with eosinophil counts ≥300 cells/μL treated with dupilumab
0 Comments
PHOENIX — Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults and adolescents treated with dupilumab achieved histological remission compared to 6.3% in the placebo group (P<0.0001), according to Marc Rothenberg, MD, PhD, of Cincinnati Children’s Hospital, in a pre-recorded
0 Comments
Obesity may put women at a higher risk for airway obstructive diseases, a Korean population-based cohort study suggested. In an adjusted model, premenopausal women with severe obesity had a 67% higher risk for chronic obstructive pulmonary disease (COPD; HR 1.67, 95% CI 1.54-1.81), while postmenopausal women had a 57% elevated risk (HR 1.57, 95% CI
0 Comments